Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

 
 
DownloadE-Mail
  Serum S100B represents a new biomarker for mood disorders

Schroeter, M. L., Sacher, J., Steiner, J., Schönknecht, P., & Mueller, K. (2013). Serum S100B represents a new biomarker for mood disorders. Current Drug Targets, 14(11), 1237-1248. doi:10.2174/13894501113149990014.

Item is

Basisdaten

einblenden: ausblenden:
Genre: Zeitschriftenartikel

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Schroeter, Matthias L.1, 2, 3, 4, Autor           
Sacher, Julia1, 2, Autor           
Steiner, Johann5, Autor
Schönknecht, Peter5, 6, Autor
Mueller, Karsten7, Autor           
Affiliations:
1Clinic for Cognitive Neurology, University of Leipzig, Germany, ou_persistent22              
2Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634549              
3Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany, ou_persistent22              
4German Consortium for Frontotemporal Lobar Degeneration (FTLD), Bonn, Germany, ou_persistent22              
5Department of Psychiatry, Otto von Guericke University Magdeburg, Germany, ou_persistent22              
6Department of Psychiatry and Psychotherapy, University of Leipzig, Germany, ou_persistent22              
7Methods and Development Unit Nuclear Magnetic Resonance, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634558              

Inhalt

einblenden:
ausblenden:
Schlagwörter: Astrocytes; Bipolar disorder; DTI; Glia; Imaging; Major depression; Mania; Mood disorder; MRI; Oligodendrocytes; S100B
 Zusammenfassung: Recently, mood disorders have been discussed to be characterized by glial pathology. The protein S100B, a growth and differentiation factor, is located in, and may actively be released by astro- and oligodendrocytes. This protein is easily assessed in human serum and provides a useful parameter for glial activation or injury. Here, we review studies investigating the glial marker S100B in serum of patients with mood disorders. Studies consistently show that S100B is elevated in mood disorders; more strongly in major depressive than bipolar disorder. Consistent with the glial hypothesis of mood disorders, serum S100B levels interact with age with higher levels in elderly depressed subjects. Successful antidepressive treatment has been associated with serum S100B reduction in major depression, whereas there is no evidence of treatment effects in mania. In contrast to the glial marker S100B, the neuronal marker protein neuron-specific enolase is unaltered in mood disorders. Recently, serum S100B has been linked to specific imaging parameters in the human white matter suggesting a role for S100B as an oligodendrocytic marker protein. In sum, serum S100B can be regarded as a promising in vivo biomarker for mood disorders deepening the understanding of the pathogenesis and plasticity-changes in these disorders. Future longitudinal studies combining serum S100B with other cell-specific serum parameters and multimodal imaging are warranted to further explore this serum protein in the development, monitoring and treatment of mood disorders.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2013-03-262013-02-042013-05-172013-10
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: DOI: 10.2174/13894501113149990014
PMID: 23701298
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Current Drug Targets
  Kurztitel : Curr Drug Targets
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Hilversum, Netherlands : Bentham Science Publishers
Seiten: - Band / Heft: 14 (11) Artikelnummer: - Start- / Endseite: 1237 - 1248 Identifikator: Anderer: 1389-4501
CoNE: https://pure.mpg.de/cone/journals/resource/13894501